Dianthus Therapeutics (DNTH) Net Cash Flow (2017 - 2025)

Dianthus Therapeutics' Net Cash Flow history runs 9 years deep, the most recent figure standing at $42.7 million for Q3 2025.

• In Q3 2025, Net Cash Flow rose 115.23% year-over-year to $42.7 million; the TTM figure through Dec 2025 stood at $33.1 million (up 130.29% YoY), while the FY2024 annual figure was -$109.4 million, down 193.5% from the prior year.
• Net Cash Flow was $42.7 million for Q3 2025 at Dianthus Therapeutics, up from $3.1 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $197.4 million in Q1 2024 to a low of -$280.3 million in Q3 2024.
• Historically, Net Cash Flow has averaged $6.4 million across 5 years, with a median of -$8.9 million in 2021.
• Biggest YoY gain for Net Cash Flow was 4136.37% in 2022; the steepest drop was 575.67% in 2022.
• A 5-year view of Net Cash Flow shows it stood at -$25.9 million in 2021, then increased by 16.89% to -$21.5 million in 2022, then slipped by 15.99% to -$25.0 million in 2023, then surged by 56.41% to -$10.9 million in 2024, then surged by 492.38% to $42.7 million in 2025.
• The last three Net Cash Flow figures came in at $42.7 million (Q3 2025), $3.1 million (Q2 2025), and -$12.7 million (Q1 2025), per Business Quant data.